gimli
RUBICON stock analysis context
RUBICON RESEARCH Stock Context for AI Screening
RUBICON RESEARCH LIMITED is a mid-cap stock in Healthcare. This page summarizes key screening signals for RUBICON RESEARCH, including recent returns, momentum indicators, valuation ratios, liquidity, and growth metrics. Gimli uses this context to help users ask natural-language stock screening questions across Indian equities.
Open interactive RUBICON stock pagePrice
₹1,272.00
1W return
+30.09%
1M return
+31.14%
3M return
+64.47%
6M return
+101.63%
1Y return
n/a
Market cap
₹20,956.24 cr
PE
142.45
PB
38.74
ROE
n/a
ROCE
n/a
RSI
78.99
Turnover
₹238.22 cr
Why it can matter in screens
- Momentum: RUBICON is above 50DMA; RSI is 78.99.
- Returns: 1D -2.35%, 1W +30.09%, 1M +31.14%, 3M +64.47%, 1Y n/a.
- Trend levels: 52W high ₹1,302.60, 52W low ₹577.25, off high -2.35%.
- Liquidity: latest turnover is ₹238.22 cr; volume vs 20D is +2.24%.
- Valuation/profitability: PE 142.45, PB 38.74, ROE n/a, ROCE n/a.
- Growth: 3Y sales CAGR n/a, 3Y profit CAGR n/a.
Financials and Ownership
Quarterly income statement
| Period | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2025-12-31 | 475.53 cr | 111.91 cr | 72.80 cr | 4.46 |
| 2025-03-31 | 340.98 cr | 70.47 cr | 36.24 cr | nan |
| 2024-12-31 | 313.40 cr | 70.39 cr | 38.07 cr | 2.31 |
Annual income statement
No recent data available.
Balance sheet
| Period | Assets | Cash | Debt | Equity |
|---|---|---|---|---|
| 2025-03-31 | 1,451.43 cr | 104.98 cr | 434.72 cr | 540.99 cr |
Cash flow
| Period | OCF | FCF | Cash change |
|---|---|---|---|
| 2025-12-31 | n/a | n/a | n/a |
| 2025-03-31 | n/a | n/a | n/a |
| 2024-12-31 | n/a | n/a | n/a |
Shareholding Trend
| Period | Promoter | FII/FPI | DII | MF | Retail | Pledge |
|---|---|---|---|---|---|---|
| 2026-03-31 | +59.86% | +7.54% | +10.02% | +7.14% | +22.58% | +100.00% |
| 2025-12-31 | +59.99% | +7.99% | +9.45% | +6.61% | +22.57% | +100.00% |
| 2025-10-15 | +59.99% | +9.37% | +10.54% | +5.63% | +20.10% | +100.00% |
Industry Peers
| Symbol | Name | Mcap | PE | ROE | 1Y |
|---|---|---|---|---|---|
| SUNPHARMA | SUN PHARMACEUTICAL IND L | 429,121.06 cr | 40.824543 | +15.06% | +7.26% |
| DIVISLAB | DIVI S LABORATORIES LTD | 174,585.42 cr | 68.707369 | +17.81% | +0.71% |
| TORNTPHARM | TORRENT PHARMACEUTICALS L | 147,849.87 cr | 68.354079 | +29.94% | +39.35% |
| APOLLOHOSP | APOLLO HOSPITALS ENTER. L | 119,204.71 cr | 64.295958 | +23.21% | +21.70% |
| CIPLA | CIPLA LTD | 111,088.72 cr | 29.624450 | +12.91% | -6.65% |
| ZYDUSLIFE | ZYDUS LIFESCIENCES LTD | 108,331.15 cr | 21.874917 | +20.44% | +16.21% |
| DRREDDY | DR. REDDY S LABORATORIES | 105,181.70 cr | 24.542479 | +13.88% | +1.20% |
| LUPIN | LUPIN LIMITED | 103,385.66 cr | 22.341869 | +29.22% | +15.72% |
Try these prompts
- Analyze RUBICON RESEARCH with valuation, momentum and industry peers
- Compare RUBICON with other Healthcare stocks
- Show mid-cap stocks in Healthcare above 50DMA with positive 1M return
- Find Healthcare stocks with improving momentum and reasonable valuation
Related screen ideas
- View Healthcare stocks
- View mid-cap stocks
- Find stocks above 50DMA
- Compare RUBICON with other Healthcare stocks
Data snapshot: 2026-06-03. Not investment advice.